Document is current
Any future updates will be listed below
-
Authors
Zhu, Quing https://orcid.org/0000-0002-1837-2588
Ademuyiwa, Foluso O.
Young, Catherine
Appleton, Catherine
Covington, Matthew F.
Ma, Cynthia
Sanati, Souzan
Hagemann, Ian S.
Mostafa, Atahar
Uddin, K. M. Shihab
Grigsby, Isabella
Frith, Ashley E.
Hernandez-Aya, Leonel F.
Poplack, Steven S.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02891681 at ClinicalTrials.govDocuments that mention this clinical trial
Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography
https://doi.org/10.1007/s10549-021-06239-y
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01 CA228047)
National Institute of Biomedical Imaging and Bioengineering (R01EB002136)
- License Information
-
More Information
Article History
Received: 2 January 2021
Accepted: 20 April 2021
First Online: 10 May 2021
Declarations
:
: QZ is the inventor of the patents related to ultrasound-guided near-infrared tomography technologies and patents owned by the University of Connecticut and/or Washington University in St Louis. She has no conflicts of interest. All authors declare that they have no conflicts of interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: This article does not contain any studies with animals performed by any of the authors.
: All authors have read the manuscript and agreed with the submission.
